MRI 1867
Alternative Names: MRI-1867Latest Information Update: 28 Aug 2024
At a glance
- Originator National Institutes of Health (USA)
- Developer National Institutes of Health (USA); Scopus BioPharma
- Class Antifibrotics; Chlorobenzenes; Pyrazoles; Skin disorder therapies; Sulfonamides
- Mechanism of Action Cannabinoid 1 receptor inverse agonists; Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic scleroderma